
样式: 排序: IF: - GO 导出 标记为已读
-
Bending Oxygen Saturation index (BOSI) and Risk of Worsening Heart Failure Events in Chronic Heart Failure Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-08-06 Rafael de la Espriella, Martina Amiguet, Gema Miñana, Juan Carlos Rodríguez, Patricia Moyano, Daniel Segarra, Julio Fernández, Enrique Santas, Gonzalo Núñez, Miguel Lorenzo, Clara Bonanad, Edgardo Alania, Alfonso Valle, Juan Sanchis, Vicent Bodí, Jose Luis Górriz, Jorge Navarro, Pau Codina, Adriaan A. Voors, Antoni Bayés-Genís, Julio Núñez
Bendopnea is a clinical symptom of advanced heart failure (HF) with uncertain prognostic value. We aimed to evaluate whether bendopnea and the change in oxygen saturation when bending forward (Bending Oxygen Saturation Index -BOSI-) are associated with adverse outcomes in ambulatory chronic heart failure (CHF) patients.
-
Liver tests and outcomes in heart failure with reduced ejection fraction: Findings from DAPA-HF Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-08-06 Carly Adamson, Lorna M Cowan, Rudolf A. de Boer, Mirta Diez, Jarosław Drożdż, Andre Dukát, Silvio E. Inzucchi, Lars Køber, Mikhail N. Kosiborod, Charlotta E.A. Ljungman, Felipe A. Martinez, Piotr Ponikowski, Marc S. Sabatine, Daniel Lindholm, Olof Bengtsson, David W. Boulton, Peter J. Greasley, Anna Maria Langkilde, Mikaela Sjöstrand, Scott D Solomon, John JV McMurray, Pardeep S Jhund
Reflecting both increased venous pressure and reduced cardiac output, abnormal liver tests are common in patients with severe heart failure and are associated adverse clinical outcomes. We aimed to investigate the prognostic significance of abnormal liver tests in ambulatory patients with heart failure with reduced ejection fraction (HFrEF), explore any treatment interaction between bilirubin and sodium-glucose
-
Atrial amyloidosis: mechanisms and clinical manifestations Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-08-03 Giuseppe Vergaro, Alberto Aimo, Claudio Rapezzi, Vincenzo Castiglione, Iacopo Fabiani, Angela Pucci, Gabriele Buda, Claudio Passino, Josep Lupón, Antoni Bayes-Genis, Michele Emdin, Eugene Braunwald
Cardiac amyloidosis (CA) is now recognized as an important cause of heart failure. Increased wall thickness and diastolic dysfunction of the left ventricle (LV) are the most easily detectable manifestations of CA, but amyloid accumulates in all cardiac structures. Involvement of the left and right atria may be due to the haemodynamic effects of ventricular diastolic dysfunction, the effects of amyloid
-
Sex differences among patients with transthyretin amyloid cardiomyopathy – from diagnosis to prognosis Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-08-02 Rishi K Patel, Adam Ioannou, Yousuf Razvi, Liza Chacko, Lucia Venneri, Francesco Bandera, Daniel Knight, Tushar Kotecha, Ana Martinez-Naharro, Ambra Masi, Aldostefano Porcari, James Brown, Kiara Patel, Charlotte Manisty, James Moon, Dorota Rowczenio, Janet A Gilbertson, Gianfranco Sinagra, Helen Lachmann, Ashutosh Wechalekar, Aviva Petrie, Carol Whelan, Philip N Hawkins, Julian D Gillmore, Marianna
Transthyretin amyloid cardiomyopathy (ATTR-CM) is predominantly diagnosed in men. The few available studies suggest affected women have a more favourable cardiac phenotype. We aimed to characterise sex differences among consecutive patients with non-hereditary and two prevalent forms of hereditary ATTR-CM diagnosed over a 20-year period.
-
Trajectories in New York heart association functional class across the ejection fraction spectrum: data from the Swedish Heart Failure registry Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-08-02 Felix Lindberg, Lars H Lund, Lina Benson, Ulf Dahlström, Patric Karlström, Cecilia Linde, Giuseppe Rosano, Gianluigi Savarese
To investigate incidence, predictors and prognostic implications of longitudinal New York Heart Association (NYHA) class changes (i.e. improving or worsening vs. stable NYHA class) in heart failure (HF) across the ejection fraction (EF) spectrum.
-
Evolution of tricuspid regurgitation after transcatheter edge-to-edge mitral valve repair for secondary mitral regurgitation and its impact on mortality Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-08-01 Marianna Adamo, Matteo Pagnesi, Giulia Ghizzoni, Rodrigo Estévez-Loureiro, Sergio Raposeiras-Roubin, Daniela Tomasoni, Davide Stolfo, Gianfranco Sinagra, Antonio Popolo Rubbio, Francesco Bedogni, Federico De Marco, Cristina Giannini, Anna Sonia Petronio, Laura Stazzoni, Tomás Benito-González, Felipe Fernández-Vázquez, Carmen Garrote-Coloma, Cosmo Godino, Eustachio Agricola, Andrea Munafò, Isaac Pascual
To evaluate short-term changes in tricuspid regurgitation (TR) after transcatheter edge-to-edge repair (M-TEER) in secondary mitral regurgitation (SMR), their predictors and impact on mortality.
-
Longitudinal Trajectories in Renal Function Before and After Heart Failure Hospitalization Among Patients with HFpEF in the PARAGON-HF Trial Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-07-27 Safia Chatur, Muthiah Vaduganathan, Alexander Peikert, Brian L Claggett, Finnian R. McCausland, Hicham Skali, Marc A. Pfeffer, Iris E Beldhuis, Lars Kober, Petar Seferovic, Martin Lefkowitz, John JV McMurray, Scott D. Solomon
Worsening renal function may impact long-term outcomes in heart failure (HF). However, little is known about the longitudinal trajectories in renal function in relation to the HF hospitalization or how this high-risk clinical event impacts renal outcomes.
-
Intravenous iron therapy improves the hypercapnic ventilatory response and sleep disordered breathing in chronic heart failure Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-07-22 Sergio Caravita, Andrea Faini, Carlo Vignati, Sara Pelucchi, Elisabetta Salvioni, Gaia Cattadori, Claudia Baratto, Camilla Torlasco, Mauro Contini, Alessandra Villani, Gabriella Malfatto, Elisa Perger, Carolina Lombardi, Alberto Piperno, Piergiuseppe Agostoni, Gianfranco Parati
Intravenous iron therapy can improve symptoms in patients with heart failure, anemia and iron deficiency. The mechanisms underlying such an improvement might involve chemoreflex sensing and nocturnal breathing patterns.
-
Safety and Efficacy of Istaroxime for Patients with Acute-Heart-Failure-Related Pre-cardiogenic Shock - A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study (SEISMiC) Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-07-22 Marco Metra, Ovidiu Chioncel, Gad Cotter, Beth Davison, Gerasimos Filippatos, Alexandre Mebazaa, Maria Novosadova, Piotr Ponikowski, Phillip Simmons, Joseph Soffer, Steven Simonson
We examined the effects of istaroxime in patients hospitalized for acute heart failure (AHF) related Society for Cardiovascular Angiography and Interventions (SCAI) stage B pre-cardiogenic shock (CS).
-
Effects of Steroidal Mineralocorticoid Receptor Antagonists on Acute and Chronic Estimated Glomerular Filtration Rate Slopes in Patients with Chronic Heart Failure Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-07-22 Muthiah Vaduganathan, João Pedro Ferreira, Patrick Rossignol, Brendon Neuen, Brian L. Claggett, Marc A. Pfeffer, John J.V. McMurray, Bertram Pitt, Faiez Zannad, Scott D. Solomon
Steroidal mineralocorticoid receptor antagonists (MRAs) form a cornerstone of the management of heart failure (HF), but little is known about the long-term effects of MRA therapy on kidney function. We evaluated acute and chronic estimated glomerular function (eGFR) slopes in the 2 largest completed trials testing steroidal MRAs in chronic HF.
-
Accelerating cardiovascular research: recent advances in translational 2D and 3D heart models Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-07-22 Elisa Mohr, Thomas Thum, Christian Bär
In vitro modelling the complex (patho-) physiological conditions of the heart is a major challenge in cardiovascular research. In recent years, methods based on three-dimensional (3D) cultivation approaches have steadily evolved to overcome the major limitations of conventional adherent two-dimensional (2D) monolayer cultivation. These 3D approaches aim to study, reproduce or modify fundamental native
-
Cardiac Contractility Modulation Therapy Improves Health Status in Patients with Heart Failure with Preserved Ejection Fraction; a Pilot Study (CCM-HFpEF) Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-07-20 Cecilia Linde, Marcin Grabowski, Piotr Ponikowski, Ishu Rao, Angela Stagg, Carsten Tschöpe
This pilot study aimed to assess the potential benefits of CCM in patients with HF with preserved left ventricular (LV) EF (HFpEF).
-
Value of the HFA-PEFF and H2FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-07-20 Daniela Tomasoni, Alberto Aimo, Marco Merlo, Matilde Nardi, Marianna Adamo, Maria Giulia Bellicini, Dario Cani, Maria Franzini, Anas Khalil, Edoardo Pancaldi, Giorgia Panichella, Aldostefano Porcari, Maddalena Rossi, Giuseppe Vergaro, Carlo Mario Lombardi, Gianfranco Sinagra, Claudio Rapezzi, Michele Emdin, Marco Metra
The HFA-PEFF and H2FPEF scores have been developed to diagnose heart failure with preserved ejection fraction (HFpEF), and hold prognostic value. Their value in patients with HFpEF caused by cardiac amyloidosis (CA) has never been investigated.
-
Clinical Effect of Obesity on NT-proBNP Cut-off Concentrations for the Diagnosis of Acute Heart Failure Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-07-18 Nikola Kozhuharov, Jasmin Martin, Desiree Wussler, Pedro Lopez-Ayala, Maria Belkin, Ivo Strebel, Dayana Flores, Matthias Diebold, Samyut Shrestha, Albina Nowak, Danielle M. Gualandro, Eleni Michou, Tobias Zimmermann, Katharina Rentsch, Arnold von Eckardstein, Dagmar I. Keller, Tobias Breidthardt, Christian Mueller
Obese patients have lower natriuretic peptides concentrations.
-
Prognostic significance of obstructive coronary artery disease in patients admitted with acute decompensated heart failure: the ARIC study community surveillance Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-07-18 Zainali S. Chunawala, Arman Qamar, Sameer Arora, Ambarish Pandey, Marat Fudim, Muthiah Vaduganathan, Robert J. Mentz, Deepak L. Bhatt, Melissa C. Caughey
-
Primary pericardial angiosarcoma in a patient with a history of colon carcinoma Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-07-18 Ling-Yun Kong, Xiao-Zheng Cui, Ren-Chi Ma, Li Li, Wei Xiang, Xiu-Juan Wang, Fang Liu
Primary pericardial angiosarcoma is a rare but aggressive cause of cardiac tamponade. Development of pericardial angiosarcoma in patients with a history of carcinoma has not been reported previously. Imaging characteristics of pericardial angiosarcoma remain to be clarified, and hypoechoic mass interrupted with irregular hyperechoic tissue on transthoracic echocardiography may be a sign indicating
-
Use of guideline-recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and persistence Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-07-18 Roemer J. Janse, Edouard L. Fu, Ulf Dahlström, Lina Benson, Bengt Lindholm, Merel van Diepen, Friedo W. Dekker, Lars H. Lund, Juan-Jesus Carrero, Gianluigi Savarese
-
Sex, Fat and the Heart: It's All in the Waist. Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-07-10 Chanchal Chandramouli,Carolyn Sp Lam
-
Reply to the letter "Methodological and reporting issues for meta-analysis of immune checkpoint inhibitor-associated cardiotoxicity". Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-07-07 Gerardo García-Rivas
-
Biomarker-driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR–Preserved trial Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-07-07 Stuart J. Pocock, João Pedro Ferreira, Milton Packer, Faiez Zannad, Gerasimos Filippatos, Toru Kondo, John J.V. McMurray, Scott D. Solomon, James L. Januzzi, Tomoko Iwata, Afshin Salsali, Javed Butler, Stefan D. Anker
-
Insights from a clinical heart valve center: characteristics and management of functional mitral regurgitation. Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-07-06 Liam J Stanton,Lyle B Dershowitz,Kendrick J Lang,Russell Brandwein,Rebecca Hahn,Nir Uriel,Susheel K Kodali,Isaac George
-
Guideline-directed medical therapy in patients undergoing transcatheter edge-to-edge repair for secondary mitral regurgitation Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-07-06 Satoshi Higuchi, Mathias Orban, Marianna Adamo, Cristina Giannini, Bruno Melica, Nicole Karam, Fabien Praz, Daniel Kalbacher, Benedikt Koell, Lukas Stolz, Daniel Braun, Michael Näbauer, Mirjam Wild, Philipp Doldi, Michael Neuss, Christian Butter, Mohammad Kassar, Tobias Ruf, Aniela Petrescu, Sebastian Ludwig, Roman Pfister, Christos Iliadis, Matthias Unterhuber, Francisco Sampaio, Diogo Ferreira, Holger
-
Systemic embolism in Transthyretin Cardiomyopathy; How to look into the future. Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-07-05 Tor Skibsted Clemmensen,Steen Hvitfeldt Poulsen
-
An international Delphi consensus regarding best practice recommendations for hyperkalaemia across the cardiorenal spectrum Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-07-05 James O. Burton, Andrew J.S. Coats, Csaba P. Kovesdy, Biff F. Palmer, Ileana L. Piña, Giuseppe Rosano, Manish M. Sood, Shelley Zieroth
Renin–angiotensin–aldosterone system inhibitors (RAASi) are guideline-recommended therapy for individuals with cardiorenal disease. They are associated with increased risk of hyperkalaemia, a common and life-threatening disorder for this population. RAASi-induced hyperkalaemia often leads to dose reduction or discontinuation, reducing cardiorenal protection. Guideline recommendations differ between
-
Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-07-05 Michele Senni, Wendimagegn G. Alemayehu, David Sim, Frank Edelmann, Javed Butler, Justin Ezekowitz, Adrian F. Hernandez, Carolyn S.P. Lam, Christopher M. O'Connor, Burkert Pieske, Piotr Ponikowski, Lothar Roessig, Adriaan A. Voors, Cynthia M. Westerhout, Ciaran McMullan, Paul W. Armstrong
-
Baseline clinical characteristics of heart failure patients with reduced ejection fraction enrolled in the BUDAPEST-CRT Upgrade trial Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-07-05 Béla Merkely, László Gellér, Endre Zima, István Osztheimer, Levente Molnár, Csaba Földesi, Gábor Duray, Jerzy K. Wranicz, Marianna Németh, Kinga Goscinska-Bis, Robert Hatala, László Sághy, Boglárka Veres, Walter Richard Schwertner, Alexandra Fábián, Eszter Fodor, Ilan Goldenberg, Valentina Kutyifa, Attila Kovács, Annamária Kosztin
The BUDAPEST-CRT Upgrade study is the first prospective, randomized, multicentre clinical trial investigating the outcomes after cardiac resynchronization therapy (CRT) upgrade in heart failure (HF) patients with intermittent or permanent right ventricular (RV) pacing with wide paced QRS. This report describes the baseline clinical characteristics of the enrolled patients and compares them to cohorts
-
The Challenge of Addressing Heart Failure in Low and Middle Income Countries. Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-07-04 Søren Lund Kristensen,Anders Barasa,Jens Jakob Thune
-
Empagliflozin in heart failure with preserved and mildly reduced ejection fraction: prognostic benefit confirmed with different endpoint definitions. Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-07-04 Antoni Bayes-Genis,Alberto Aimo,Josep Lupón
-
Midazolam versus morphine in acute cardiogenic pulmonary oedema: results of a multicentre, open-label, randomized controlled trial Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-07-03 Alberto Domínguez-Rodríguez, Coral Suero-Mendez, Guillermo Burillo-Putze, Victor Gil, Rafael Calvo-Rodriguez, Pascual Piñera-Salmeron, Pere Llorens, Francisco J. Martín-Sánchez, Pedro Abreu-Gonzalez, Òscar Miró
-
BLITZ-HF: a nationwide initiative to evaluate and improve adherence to acute and chronic heart failure guidelines Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-07-03 Michele Massimo Gulizia, Francesco Orso, Andrea Mortara, Donata Lucci, Nadia Aspromonte, Leonardo De Luca, Giuseppe Di Tano, Giuseppe Leonardi, Alessandro Navazio, Giovanni Pulignano, Furio Colivicchi, Andrea Di Lenarda, Fabrizio Oliva
To assess adherence to guideline recommendations among a large network of Italian cardiology sites in the management of acute and chronic heart failure (HF) and to evaluate if an ad-hoc educational intervention can improve their performance on several pharmacological and non-pharmacological indicators.
-
Catheter ablation for patients with atrial fibrillation and heart failure: insights from the Swedish Heart Failure Registry Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-07-02 Gesa von Olshausen, Lina Benson, Ulf Dahlström, Lars H. Lund, Gianluigi Savarese, Frieder Braunschweig
-
Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-07-02 Liza Chacko, Nina Karia, Lucia Venneri, Francesco Bandera, Beatrice Dal Passo, Lodovico Buonamici, Jonathan Lazari, Adam Ioannou, Aldostefano Porcari, Rishi Patel, Yousuf Razvi, James Brown, Daniel Knight, Ana Martinez-Naharro, Carol Whelan, Candida C. Quarta, Charlotte Manisty, James Moon, Dorota Rowczenio, Janet A. Gilbertson, Helen Lachmann, Ashutosh Wechelakar, Aviva Petrie, William E. Moody, Richard
-
A global perspective on the management and outcomes of peripartum cardiomyopathy: a systematic review and meta-analysis Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-07-02 Julian Hoevelmann, Mark E. Engel, Elani Muller, Ameer Hohlfeld, Michael Böhm, Karen Sliwa, Charle Viljoen
-
Withdrawn: Major gaps in the information provided to patients before implantation of cardioverter defibrillators: a prospective patient European evaluation Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-07-02
Januszkiewicz, Ł., Barra, S., Marijon, E., Providencia, R., de Asmundis, C., Chun, J.K.R., Farkowski, M.M., Conte, G. and Boveda, S. (2022), Major gaps in the information provided to patients before implantation of cardioverter defibrillators: a prospective patient European evaluation. Eur J Heart Fail. Accepted Author Manuscript. https://doi.org/10.1002/ejhf.2600 The above article from the European
-
Abstracts of the Heart Failure 2022 and the World Congress on Acute Heart Failure, 21 - 24 May 2022, Madrid, Spain. Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-07-01
-
Exercise testing in heart failure with preserved ejection fraction: an appraisal through diagnosis, pathophysiology and therapy – A clinical consensus statement of the Heart Failure Association and European Association of Preventive Cardiology of the European Society of Cardiology Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-07-01 Marco Guazzi, Matthias Wilhelm, Martin Halle, Emeline Van Craenenbroeck, Hareld Kemps, Rudolph A. de Boer, Andrew J.S. Coats, Lars Lund, Donna Mancini, Barry Borlaug, Gerasimos Filippatos, Burkert Pieske
-
A pilot clinical trial of cell therapy in heart failure with preserved ejection fraction Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-07-01 Bojan Vrtovec, Sabina Frljak, Gregor Poglajen, Gregor Zemljic, Andraz Cerar, Matjaz Sever, Francois Haddad, Joseph C. Wu
-
Prevention of sudden death in heart failure with reduced ejection fraction: do we still need an implantable cardioverter-defibrillator for primary prevention? Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-06-26 Magdy Abdelhamid, Giuseppe Rosano, Marco Metra, Stamatis Adamopoulos, Michael Böhm, Ovidiu Chioncel, Gerasimos Filippatos, Ewa A. Jankowska, Yury Lopatin, Lars Lund, Davor Milicic, Brenda Moura, Tuvia Ben Gal, Arsen Ristic, Amina Rakisheva, Gianluigi Savarese, Wilfried Mullens, Massimo Piepoli, Antoni Bayes-Genis, Thomas Thum, Stefan D. Anker, Petar Seferovic, Andrew J.S. Coats
Sudden death is a devastating complication of heart failure (HF). Current guidelines recommend an implantable cardioverter-defibrillator (ICD) for prevention of sudden death in patients with HF and reduced ejection fraction (HFrEF) specifically those with a left ventricular ejection fraction ≤35% after at least 3 months of optimized HF treatment. The benefit of ICD in patients with symptomatic HFrEF
-
Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-06-24 Riccardo M. Inciardi, Matteo Pagnesi, Carlo M. Lombardi, Stefan D. Anker, John G. Cleland, Kenneth Dickstein, Gerasimos S. Filippatos, Chim C. Lang, Leong L. Ng, Pierpaolo Pellicori, Piotr Ponikowski, Nilesh J. Samani, Faiez Zannad, Dirk J. van Veldhuisen, Scott D. Solomon, Adriaan A. Voors, Marco Metra
-
Long-term survival and life expectancy following an acute heart failure hospitalization in Australia and New Zealand Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-06-24 Saranya Hariharaputhiran, Yang Peng, Linh Ngo, Anna Ali, Sadia Hossain, Renuka Visvanathan, Robert Adams, Wandy Chan, Isuru Ranasinghe
-
Giant cell myocarditis after first dose of BNT162b2 – a case report Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-06-22 Valentin G. Hirsch, Sven Schallhorn, Carolin Zwadlo, Johanna Diekmann, Florian Länger, Danny David Jonigk, Tibor Kempf, Heinz-Peter Schultheiss, Johann Bauersachs
Herein we report the case of a young man, admitted to the Department of Cardiology and Angiology at Hannover Medical School with shortness of breath and elevated troponin. Few weeks earlier the patient received the first dose of BioNTech's mRNA vaccine (Comirnaty, BNT162b2). After diagnostic work-up revealed giant cell myocarditis, the patient received immunosuppressive therapy. In the present context
-
Acetazolamide in Decompensated Heart Failure with Volume Overload trial (ADVOR): baseline characteristics Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-06-22 Wilfried Mullens, Jeroen Dauw, Pieter Martens, Evelyne Meekers, Petra Nijst, Frederik H. Verbrugge, Fabien Chenot, Samer Moubayed, Riet Dierckx, Philippe Blouard, David Derthoo, Walter Smolders, Bavo Ector, Michaël Hulselmans, Stijn Lochy, David Raes, Emeline Van Craenenbroeck, Hans Vandekerckhove, Pieter-Jan Hofkens, Kathleen Goossens, Anne-Catherine Pouleur, Michel De Ceuninck, Laurence Gabriel,
-
Side effects and treatment initiation barriers of sodium–glucose cotransporter 2 inhibitors in heart failure: a systematic review and meta-analysis Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-06-22 Davor Vukadinović, Amr Abdin, Stefan D. Anker, Giuseppe M.C. Rosano, Felix Mahfoud, Milton Packer, Javed Butler, Michael Böhm
Physicians are sometimes reluctant to initiate guideline-directed therapy in patients with heart failure and reduced ejection fraction (HFrEF) due to concerns of adverse events. We explored the risk of hypotension, volume depletion, and acute kidney injury (AKI) on sodium–glucose cotransporter 2 (SGLT2) inhibitors in HFrEF populations.
-
Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-06-22 Alexios S. Antonopoulos, Ioannis Panagiotopoulos, Alexandrina Kouroutzoglou, Georgios Koutsis, Pantelis Toskas, Georgios Lazaros, Konstantinos Toutouzas, Dimitris Tousoulis, Konstantinos Tsioufis, Charalambos Vlachopoulos
Systematic evidence on the prevalence and clinical outcome of transthyretin amyloidosis (ATTR) is missing. We explored: (i) the prevalence of cardiac amyloidosis in various patient subgroups, (ii) survival estimates for ATTR subtypes, and (iii) the effects of novel therapeutics on the natural course of disease.
-
Revascularisation and HFpEF - Time for Randomised Trials. Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-06-21 Matthew Ryan,Divaka Perera,Mark C Petrie
-
Predicting pacemaker implantation in cardiac amyloidosis: Let's start with an ECG. Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-06-21 Fernando Dominguez
-
Clonal haematopoiesis is associated with higher mortality in patients with cardiogenic shock Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-06-21 Fernando L. Scolari, Sagi Abelson, Darshan H. Brahmbhatt, Jessie J.F. Medeiros, Chun-Po S. Fan, Nicole L. Fung, Vesna Mihajlovic, Markus S. Anker, Madison Otsuki, Patrick R. Lawler, Heather J. Ross, Adriana C. Luk, Stefan Anker, John E. Dick, Filio Billia
-
Dilated cardiomyopathy - details make the difference. Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-06-19 Kathryn A McGurk,Brian P Halliday
-
Closing the gap, or the beauty of alleviating our patients' symptoms Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-06-19 Johannes Petutschnigg, Frank Edelmann
This article refers to ‘Durability of benefit after transcatheter tricuspid valve intervention: insights from actigraphy’ by T.J. Stocker et al., published in this issue on pages 1293–1301. Following the tremendous success using transcatheter techniques to treat aortic and mitral valve pathologies over the last decades the interventionalists' mind- and handcraft have shifted toward the tricuspid valve
-
Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death: what are the barriers to implementation in the 'real world'? Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-06-19 Giuseppe Boriani,Marco Vitolo,Francisco Leyva
-
Moving beyond the Vasodilator Model in Heart Failure with reduced Ejection Fraction - Lessons from Sildenafil. Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-06-19 Yogesh N V Reddy
-
Do we need to EVALUATE multiple biomarkers and/or the same biomarkers multiple times in patients with HF? Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-06-19 Alberto Aimo,Vincenzo Castiglione,Antoni Bayes-Genis
-
Baroreflex activation therapy with the Barostim™ device in patients with heart failure with reduced ejection fraction: a patient level meta-analysis of randomized controlled trials Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-06-17 Andrew J.S. Coats, William T. Abraham, Michael R. Zile, Joann A. Lindenfeld, Fred A. Weaver, Marat Fudim, Johann Bauersachs, Sue Duval, Elizabeth Galle, Faiez Zannad
-
Early changes in estimated glomerular filtration rate post-initiation of empagliflozin in EMPEROR-Reduced Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-06-16 Faiez Zannad, João Pedro Ferreira, John Gregson, Bettina Johanna Kraus, Michaela Mattheus, Sibylle Jenny Hauske, Javed Butler, Gerasimos Filippatos, Christoph Wanner, Stefan D. Anker, Stuart J. Pocock, Milton Packer
Sodium–glucose cotransporter 2 inhibitors (SGLT2i) may induce an early post-initiation decrease of estimated glomerular filtration rate (eGFR), which does not impact the SGLT2i benefits. The occurrence, characteristics, determinants, and clinical significance of an initial eGFR change among patients with heart failure with reduced ejection fraction require further study. In this study we aimed to describe
-
Letter regarding the article 'Cardiac energetics in patients with chronic heart failure and iron deficiency: an in-vivo 31 P magnetic resonance spectroscopy study'. Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-06-15 Matthew K Burrage,Ladislav Valkovič,Oliver J Rider
-
Left ventricular ejection fraction as the primary heart failure phenotyping parameter. Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-06-15 Lars H Lund,Bertram Pitt,Marco Metra
-
Epicardial adipose tissue in heart failure: risk factor or mediator? Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-06-15 Riccardo M Inciardi,Alvin Chandra
-
Biomarkers for the prediction of heart failure and cardiovascular events in patients with type 2 diabetes: a position statement from the Heart Failure Association of the European Society of Cardiology Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-06-15 Peter Seferović, Dimitrios Farmakis, Antoni Bayes-Genis, Tuvia Ben Gal, Michael Böhm, Ovidiu Chioncel, Roberto Ferrari, Gerasimos Filippatos, Loreena Hill, Ewa Jankowska, Mitja Lainscak, Yuri Lopatin, Lars H. Lund, Alexandre Mebazaa, Marco Metra, Brenda Moura, Giuseppe Rosano, Thomas Thum, Adriaan Voors, Andrew J.S. Coats
-
The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trial Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-06-15 Masatake Kobayashi, Nicolas Girerd, João Pedro Ferreira, Duarte Kevin, Olivier Huttin, Arantxa González, Erwan Bozec, Andrew L. Clark, Franco Cosmi, Joe Cuthbert, Javier Diez, Frank Edelmann, Mark Hazebroek, Stephane Heymans, Beatrice Mariottoni, Pierpaolo Pellicori, Johannes Petutschnigg, Burkert Pieske, Jan A. Staessen, Job A.J. Verdonschot, Patrick Rossignol, John G.F. Cleland, Faiez Zannad
-
Sacubitril/valsartan use patterns among older adults with heart failure in clinical practice: a population-based cohort study of >25 000 Medicare beneficiaries Eur. J. Heart Fail. (IF 17.349) Pub Date : 2022-06-11 Ankeet S. Bhatt, Muthiah Vaduganathan, Scott D. Solomon, Sebastian Schneeweiss, Julie C. Lauffenburger, Rishi J. Desai